External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
An External Control, Observational, Retrospective Study Assessing the Effect of Pralsetinib Compared With Best Available Therapy for Patients With RET-Fusion Positive Advanced Non-Small Cell Lung Cancer
Sponsor: Analysis Group, Inc.
A observational or N/A phase clinical study on Bronchial Diseases and Carcinoma, this trial is ongoing. The trial is conducted by Analysis Group, Inc. and has accumulated 5 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Sep 2023 — Jul 2024 [monthly]
Unknown Status
Status: Enrolling By Invitation → Unknown Status
-
Sep 2021 — Sep 2023 [monthly]
Enrolling By Invitation
-
Feb 2021 — Sep 2021 [monthly]
Enrolling By Invitation
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Analysis Group, Inc.
- Blueprint Medicines Corporation
For direct contact, visit the study record on ClinicalTrials.gov .